Sigma Planning Corp Decreases Holdings in Abbott Laboratories $ABT

Posted by Francis Steltz on Jul 18th, 2026

Sigma Planning Corp trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 36.1% during the first quarter, HoldingsChannel reports. The firm owned 13,341 shares of the healthcare product maker’s stock after selling 7,531 shares during the quarter. Sigma Planning Corp’s holdings in Abbott Laboratories were worth $1,370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Freemont Management S.A. raised its stake in Abbott Laboratories by 197.2% in the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after acquiring an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab purchased a new position in shares of Abbott Laboratories in the fourth quarter worth about $116,580,000. Thrivent Financial for Lutherans raised its position in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares during the period. Mn Services Vermogensbeheer B.V. raised its position in shares of Abbott Laboratories by 2.1% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 671,743 shares of the healthcare product maker’s stock valued at $84,163,000 after purchasing an additional 13,543 shares during the period. Finally, Net Worth Advisory Group purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $1,366,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 1.9%

ABT opened at $100.71 on Friday. The firm has a market capitalization of $175.41 billion, a P/E ratio of 32.59, a price-to-earnings-growth ratio of 1.70 and a beta of 0.61. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a fifty day moving average price of $89.89 and a 200-day moving average price of $102.17. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm’s revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of recent research reports. Benchmark reduced their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 7th. Citigroup boosted their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday. Bank of America cut their target price on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, Leerink Partners reduced their target price on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $118.61.

Get Our Latest Stock Analysis on ABT

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.